The draft patent amendment rules made public on August 23 this yr may massively profit huge pharma however become disastrous for sufferers in India and in nations within the world South, which depend on generic medication manufactured in India, in accessing reasonably priced medication and vaccines.
The draft rules launched by the Department for Promotion of Industry and Internal Trade for stakeholder feedback have made a number of important adjustments that can create useless hurdles in pre-grant opposition of patents. First, the draft amendment rules have launched a variable payment for submitting pre-grant oppositions. The proposed introduction of charges can run into hundreds of rupees and thus impose a major monetary burden on civil society organisations and sufferers’ teams submitting pre-grant opposition.
The most vital change is about granting the controller the ability to find out the maintainability of illustration by people or civil society organisations to file pre-grant oppositions.
“Pre-grant opposition is an important public health safeguard against patent evergreening and unmerited monopolies. It is one sure way to ensure that quality-assured and affordable generics remain accessible,” says Leena Menghaney, India Head and Global IP Advisor, Medecins Sans Frontieres – Access Campaign. But the amendment within the draft patent rules threatens the safeguard towards extending the length of patent safety on utterly frivolous grounds. Big pharma has lobbied for years to take away important safeguards from India’s patent legal guidelines.
“The purpose of the draft amendment rules to pre-grant opposition is to knock out people whom they don’t want [to challenge the granting of patents]. This is wrong. How will the controller decide the maintainability and on what basis? There is no guiding factor. This will create more problems,” Anand Grover, senior advocate on the Supreme Court instructed The Hindu; Mr. Grover had represented the petitioners within the Bedaquiline pre-grant opposition. “Today there is no problem. Anyone can file a pre-grant opposition and the controller has to adjudicate on merit.”
Mr. Grover additional added: “The [government] is favouring the companies, and pharma companies don’t want pre-grant opposition. But since they can’t do away with that, they are making the process difficult. They are introducing the maintainability criterion but there should be a rational basis. If the pre-grant opposition has grounds of pre-grant, then how is it not maintainable? The controller will decide on an arbitrary basis [about maintainability], which is wrong.”
The draft rules on who’s eligible to file a pre-grant opposition comes at a time when on September 13 this yr Nandita Venkatesh from India and Phumeza Tisile from South Africa have been listed within the Time journal’s 100 rising leaders globally who’re defining the subsequent technology of management. The purpose for being chosen within the choose membership: their stellar position in efficiently thwarting Johnson & Johnson’s try to increase the patent safety for its oral drug Bedaquiline by evergreening. Bedaquiline is an important drug for treating multidrug-resistant TB.
Both Nandita and Phumeza are TB survivors who misplaced their listening to attributable to using the extremely poisonous Kanamycin injection to deal with MDR-TB. They each filed the pre-grant opposition together with Network of Maharashtra folks residing with HIV (NMP+). The duo was supported by Médecins Sans Frontières.
In March this yr, the Indian Patent Office struck down J&J’s evergreening makes an attempt by ruling that making a spinoff of quinoline in its salt type (fumarate) was apparent and didn’t contain any ingenious step, and is due to this fact non-patentable.
Currently, the Patents Act explicitly permits “any person” to file a pre-grant opposition with out the discretion of the Controller. But as per the draft patent amendment rules, the maintainability of the petitioners who file a pre-grant opposition won’t be automated however will probably be decided by the Controller.
While “any person” can at the moment file a pre-grant opposition, solely individuals can file a petition in relation to opposing patents which have already been granted. “In many instances, big pharma had questioned the maintainability of petitioners opposing patents and delayed cases for long periods. Bringing in maintainability of representation in pre-grant opposition will face the same fate as big pharma can always contest the Controller’s decision regarding maintainability of petitioners,” says Ms. Menghaney.
“Bringing in maintainability of representation in the pre-grant opposition will be the first major amendment to the Indian Patent Act. The provision of pre-grant opposition in the India Patent Act is unique in the world, the reason why big pharma has been opposed to it as they want continued control over the market and charge high prices for their products. Any weakening of the provision will be disastrous for patients as they will not be able to afford the high price of medicines and the generic drug industry will be affected too,” says Dr Biswajit Dhar, Vice President, Council for Social Development.
There have been innumerable situations when pre-grant opposition filed by affected person teams and civil society organisations have resulted within the rejection of patent safety extension sought by huge pharma primarily based on frivolous claims of “novel invention”.
For occasion, in May 2006, within the case of Tenofovir disoproxil fumarate (TDF), a primary line antiretroviral used for remedy of individuals residing with HIV, the pre-grant opposition was filed towards Sahara by the Indian Network of People Living with HIV/AIDS and the Delhi Network of Positive People. The pre-grant opposition was primarily based on the bottom that the drug consists of a beforehand recognized compound.
In one other occasion, Boehringer Ingelheim’s patent software for its paediatric type of the anti-AIDS drug Nevirapine was rejected in 2008 primarily based on a pre-grant opposition filed by socio-legal group Lawyers Collective on behalf of sufferers’ teams in May 2006. The rejection was on the grounds that new types of recognized substances can’t be patented except there’s a important enhancement of efficacy.
Other high-profile makes an attempt at evergreening that failed attributable to pre-grant opposition filed by sufferers’ teams and civil society organisations embrace Glivec (imatinib mesylate), Zidovudine/Lamivudine (first line HIV medicines) and Lopinavir/Ritonavir (second line HIV medicines).
